Metformin suppresses intestinal polyp growth in ApcMin/+ mice

Metformin is a biguanide derivative that is widely used in the treatment of diabetes mellitus. One of the pharmacological targets of metformin is adenosine monophosphate‐activated protein kinase (AMPK). We investigated the effect of metformin on the suppression of intestinal polyp formation in ApcMin/+ mice. Administration of metformin (250 mg/kg) did not reduce the total number of intestinal polyp formations, but significantly reduced the number of intestinal polyp formations larger than 2 mm in diameter in ApcMin/+ mice. To examine the indirect effect of metformin, the index of insulin resistance and serum lipid levels in ApcMin/+ mice were assessed. These factors were not significantly attenuated by the treatment with metformin, indicating that the suppression of polyp growth is not due to the indirect drug action. The levels of tumor cell proliferation as determined by 5‐bromodeoxyuridine and proliferating cell nuclear antigen immunohistochemical staining, and apoptosis, via transferase deoxytidyl uridine end labeling staining, in the polyps of metformin‐treated mice were not significantly different in comparison to those of control mice. Gene expression of cyclin D1 and c‐myc in intestinal polyps were also not significantly different between those two groups. In contrast, metformin activated AMPK in the intestinal polyps, resulting in the inhibition of the activation of mammalian target of rapamycin, which play important roles in the protein synthesis machinery. Metformin suppressed the polyp growth in ApcMin/+ mice, suggesting that it may be a novel candidate as a chemopreventive agent for colorectal cancer. (Cancer Sci 2008; 99: 2136–2141)